Related references
Note: Only part of the references are listed.Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis
Michael Colacci et al.
CANADIAN JOURNAL OF DIABETES (2022)
Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System
Concetta Rafaniello et al.
PHARMACEUTICALS (2021)
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and-2 studies
Moshe Phillip et al.
DIABETES OBESITY & METABOLISM (2021)
PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database
Gabriella di Mauro et al.
DRUG SAFETY (2021)
Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists
Tamara Y. Milder et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
Annamaria Mascolo et al.
PHARMACOLOGICAL RESEARCH (2021)
Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials
Yuxin Huang et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)
Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
Xiang Zhou et al.
FRONTIERS IN PHARMACOLOGY (2021)
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance
Annamaria Mascolo et al.
DRUG SAFETY (2021)
Acute Renal Failure, Ketoacidosis, and Urogenital Tract Infections with SGLT2 Inhibitors: Signal Detection Using a Japanese Spontaneous Reporting Database
Yukari Katsuhara et al.
CLINICAL DRUG INVESTIGATION (2020)
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial
Chantal Mathieu et al.
DIABETES OBESITY & METABOLISM (2020)
Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits
Yumin Gao et al.
AMERICAN HEART JOURNAL (2020)
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis A Multicenter Cohort Study
Antonios Douros et al.
ANNALS OF INTERNAL MEDICINE (2020)
Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
Rosanna Ruggiero et al.
FRONTIERS IN PHARMACOLOGY (2020)
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
Anne L. Peters et al.
DIABETES CARE (2020)
A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed
Samantha Steinmetz-Wood et al.
CASE REPORTS IN ENDOCRINOLOGY (2020)
Management of Diabetic Ketoacidosis in Adults: A Narrative Review
Mohsen S. Eledrisi et al.
SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES (2020)
Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy
Cristina Scavone et al.
DRUGS-REAL WORLD OUTCOMES (2020)
SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: A Case Report
Katherine M. Wang et al.
KIDNEY MEDICINE (2020)
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors
Thomas Danne et al.
DIABETES CARE (2019)
Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy
Cristina Scavone et al.
EXPERT OPINION ON DRUG SAFETY (2019)
Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists
Orly Vardeny et al.
JACC-HEART FAILURE (2019)
Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Annamaria Mascolo et al.
FRONTIERS IN PHARMACOLOGY (2019)
Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol
Ronald M. Goldenberg et al.
DIABETES OBESITY & METABOLISM (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin: A Review in Type 1 Diabetes
Julia Paik et al.
DRUGS (2019)
The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study
Stuart J. McGurnaghan et al.
DIABETOLOGIA (2019)
Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis
Iqra Iqbal et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2019)
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
Chantal Mathieu et al.
DIABETES CARE (2018)
Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system?
Maurizio Sessa et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
Paresh Dandona et al.
DIABETES CARE (2018)
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
Peter Ueda et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
Michael Fralick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature
Kelly R. Burke et al.
PHARMACOTHERAPY (2017)
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Paresh Dandona et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data
Jenny E. Blau et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives
Hongyu Qiu et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin
Shreya Pujara et al.
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS (2017)
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis
Ronald M. Goldenberg et al.
CLINICAL THERAPEUTICS (2016)
Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin
Nimrah Bader et al.
PAKISTAN JOURNAL OF MEDICAL SCIENCES (2016)
Dapagliflozin: A new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
Eva M. Vivian
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2015)
SGLT2 Inhibitors May Predispose to Ketoacidosis
Simeon I. Taylor et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes
Greg L. Plosker
DRUGS (2014)
Dapagliflozin: Glucuretic action and beyond
Pitchai Balakumar et al.
PHARMACOLOGICAL RESEARCH (2014)
Share Paper
